Request to Join
has invited you to join this group
Dr. Waikar is a clinician-investigator with interest in acute kidney injury (AKI), chronic kidney disease (CKD), renal replacement therapy, and electrolyte abnormalities. Dr. Waikar's research projects include epidemiologic investigations utilizing large databases as well as translational/patient-oriented research projects. Ongoing studies in my research group include: the epidemiology of AKI and hyponatremia; novel blood and urinary biomarkers of AKI and CKD; and small solute flux during hemodialysis and continuous renal replacement therapy. Dr. Waikar's lab has a number of ongoing observational cohorts with biological sample collection in patients with and at risk for AKI and CKD, including in patients undergoing cardiac surgery, cardiac catheterization, intensive care unit hospitalization, cisplatin chemotherapy, and kidney biopsy.
Petra Simic, MD, PhD, is a second-year fellow in nephrology at Massachusetts General Hospital and Brigham and Women's Hospital. She has extensively published in the areas of mesenchymal progenitor cells and their potential in mechanism and treatment of diseases, with a focus on bone research and endocrinology.
Dr. Michael Darmon is an Intensivist since 2005 with a nephrology background (primary specialty). He was appointed professor of Intensive Care Medicine in Saint-Etienne University Hospital (Saint-Etienne, France) in 2011. His main clinical and research focus are acute kidney injury and management of the critically ill immunocompromised patients. M. Darmon has authored or co-authored more than 150 peer-reviewed publications or book chapters. M. Darmon is member of the administration council of the Outcomerea study group and of the GRRR-OH study group (Groupe de recherche en reanimation respiratoire et Onco-hématologique). He is currently coordinating several studies funded by his institution and focusing on biomarkers performance in predicting short term renal recovery, lung-kidney interactions, and epidemiology of contrast-associated nephropathy.
Patrick Honoré, graduated from Louvain Medical School as MD (1988), Specialist in Internal Medicine (1993), Intensive Care Specialist (1994) and Nephrologist (1995). During his internship, he completed more than 2 1/2 years specialisation in Nephrology and Dialysis. For almost 5 years, he received ICU training abroad (United Kingdom, Australia and USA). Pr Honoré is Board member of the Belgian Intensive Care Society and closely involved in the Nephrology section of the European Society of Intensive Care Medicine. He is also a distinguished member or consultant of many scientific committees and decision-making organizations dedicated to diagnosis, treatment, and research in the field of acute kidney injury in the critically ill. Pr Honoré authored or co-authored more than 180 peer-reviewed papers ,more than 600 abstracts and more than 75 book chapters . He was also editor of three books dedicated to Critical Care Nephrology.He has been invited as a speaker at more than 350 national and international conferences in almost 100 different countries. He acts as reviewer for more than 45 international journals, including top-ranking journals in the field of critical care medicine and nephrology. He is a member of the editorial board of several (15 )high-standard journals. He is also Editor-In-Chief of the Journal of Translational Internal Medicine (open access) since 2013, editor-in-chief of Journal of Translational Critical Care Medicine & Journal of Translational Kidney Research since 2015 (open access too).He is also appointed as section editor for Renal in Annals of Intensive Care starting from February 2016.Since 2009, he fulltime fulfils the position of Head of Clinics in the Intensive Care department of the University Hospital, Vrije Universiteit Brussels (VUB) and became Clinical Tutor and Senior Lecturer at the VUB Faculty of Medicine.Since 2012, he fulfils the position of Full Professor at the VUB Faculty of Medicine. In the ICU department, he leads the Critical Care Nephrology Platform which incorporates intensivists, nephrologists and nurses dedicated to daily education, research and treatment of acute kidney injury. In particular, he directs and organizes continuous renal replacement therapy on a 24/24; 7/7 on-call basis.He has also start a CRRT program using citrate dedicated to small children (less than 10 kg) in the UZB -PICU since 2013.
Paul M. Palevsky, MD, is Professor of Medicine and Clinical and Translational Science in the Renal- Electrolyte Division at the University of Pittsburgh School of Medicine and is Chief of the Renal Section at the VA Pittsburgh Healthcare System. Dr. Palevsky completed his undergraduate and medical education at Northwestern University followed by internship and residency training in internal medicine and fellowship training in nephrology at the University of Pennsylvania. Dr. Palevsky joined the faculty at the University of Pittsburgh in 1989, where he has remained since. Dr. Palevsky’s research has primarily focused on acute kidney injury and critical care nephrology. He was the study chair of the VA/NIH Acute Renal Failure Trial Network (ATN) study evaluating intensity of renal replacement therapy in critically ill patients with acute kidney injury and currently serves as co-chair of the PRESERVE trial, evaluating the comparative effectiveness of saline and bicarbonate and the efficacy of N-acetylcysteine in preventing kidney damage following angiography. Among other clinical trials, Dr. Palevsky was a member of the planning and executive committee of the VA NEPHRON-D study, which compared monotherapy with an angiotensin receptor blocker to combination therapy with both an angiotensin blocker and an angiotensin converting enzyme inhibitor in slowing progression of diabetic kidney disease, and is a member of the steering committees for the EUPHRATES trial, evaluating extracorporeal endotoxin adsorption in severe sepsis. Dr Palevsky has published more than 200 original articles, reviews and book chapters, serves as a deputy editor of the Clinical Journal of the American Society of Nephrology and is section editor for Renal Failure for UpToDate. He is a former member of the board of directors and past chair of the Quality, Safety and Accountability committee of the Renal Physicians Association, is the vice-chair of the board of directors of Quality Insights Renal Network 4 (ESRD Network 4) and is a member of the National Kidney Foundation’s Scientific Advisory Board.
Dr. Suvi Vaara is a specialist in Anesthesiology and Intensive Care Medicine and is working as an intensivist at the Helsinki University Hospital in Finland. She defended her PhD thesis “Renal Replacement Therapy in the Critically Ill” in 2012. Her current research topics include the optimal timing of the renal replacement therapy, fluid therapy in acute kidney injury, and long-term outcomes after acute kidney injury. She is currently working for the multinational Standard versus Accelerated Initiation of Renal Replacement therapy in acute kidney injury –trial (STARRT-AKI) in Finland. Since her PhD thesis, she has published 16 articles in 2013-2016 including several analyses from the prospective, observational, Finnish Acute Kidney Injury study that enrolled 2901 patients from 17 centers in Finland.
Eric Hoste is a Professor in Medicine and Chief of Clinic, Intensive Care Unit, Ghent University Hospital, Belgium, as well as being a Senior Clinical Investigator of the Research Foundation-Flanders (FWO). He is also a collaborating faculty member of CRISMA (Clinical Research, Investigation, and Systems Modelling of Acute illness). He is a member and former deputy of the Acute Kidney Injury Section of the European Society of Intensive Care Medicine (ESICM), and a former president of the Belgian Society of Intensive Care Medicine. Professor Hoste’s primary clinical area of interest is clinical critical care nephrology, and has published more than 190 original papers, review articles and book chapters primarily within this field.
Intensivist at Dr. R.T. Noel Gibney is a Professor of Critical Care Medicine and Medicine at the Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. He graduated from University College Dublin Medical School, Ireland. He was registrar in Nephrology and Metabolic Medicine at St. Vincent’s University Hospital, Dublin, Ireland. He trained in Pulmonary Medicine at the University of Alberta, Edmonton, Alberta and in Critical Care Medicine at Massachusetts General Hospital, Boston and Harvard Medical School, Cambridge, USA. He has been awarded the Gold Humanism in Medicine Award at the Faculty of Medicine and Dentistry at the University of Alberta and was a member of the Renal Disaster Relief Task Force of the International Society of Nephrology following the earthquake in Haiti in 2010. He practices as an intensivist in the University of Alberta Hospital, Edmonton. Dr. Gibney’s research interests include the epidemiology and management of Acute Kidney Injury in the critically ill and Information Technology in the critical care unit. He has participated in the Acute Dialysis Quality Initiative (ADQI) and the Acute Kidney Injury Network (AKIN). He has authored or co-authored 120 peer reviewed articles and a number of book chapters and has provided over 100 invited presentations to national and international professional groups. He was Zone Clinical Department Head for Critical Care for Alberta Health Services, Edmonton from 1995-2012 and Director of the Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta from 2002-2012. He is a Past President of the Alberta Society of Intensive Care Physicians and has been a Board Member in the Alberta Medical Association and the Shock Trauma Air Rescue Society (STARS). Dr. Gibney is a member of the Health Canada Expert Advisory Committee on Cells Tissues and Organs and was a member of the Canadian Blood Services Clinical Advisory Committee, Transplant Services.
Dr Matthieu Legrand is associated Professor in Anesthesiology and Critical care medicine and holds a PhD in physiology. He Works in the Department of anesthesiology, Critical care and burn unit of St-Louis hospital, (university Paris Diderot) , in Paris, France. He has carried preclinical and clinical research in the field of critical care medicine with a special interest in the pathophysiology and treatment of acute kidney injury and in burn critical care. He has served as a reviewer for several peer-review journals and expert in the field of critical care for several commitees and task forces.
Dr. Bagshaw is a Clinician Scientist and Associate Professor in the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, at the University of Alberta, Edmonton, Canada. He trained at the University of Calgary (Internal Medicine, Critical Care Medicine, Masters of Science Epidemiology) and the Austin Hospital (Critical Care Nephrology) in Melbourne, Australia. Dr. Bagshaw is supported by a Canada Research Chair in Critical Care Nephrology. He has research expertise in epidemiology, clinical trials and health services research. His research focuses on health outcome evaluation, ICU organization and capacity in critically ill patients with a focus on acute kidney injury, technological organ support, vulnerable populations (e.g., elderly, frail), and end-of-life care. His research is supported from grants from the Canadian Institutes for Health Research, Alberta Innovates – Health Solutions, and the Canadian Frailty Network. Dr. Bagshaw is a co-Principal Investigator for the multi-national Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI) trial (ClinicalTrials.gov Identifier: NCT02568722). He has authored or co-authors over 250 peer-reviewed publications and provided over 200 invited lectures at national and international meetings. Dr. Bagshaw is a member of several organizations including the Canadian Critical Care Society, Canadian Critical Care Trials Group, and the Acute Dialysis Quality Initiative.
Dr Mehta is a Professor of Medicine in the Division of Nephrology and Associate Chair for Clinical Research in the Department of Medicine at University of California San Diego where he directs the Acute Dialysis Program and the UCSD Masters in Clinical Research Program. He is an internationally recognized expert in the field of acute kidney injury (AKI). He holds a patent for “Continuous Hemodialysis Using Citrate”. He has worked with the ISN in developing courses in clinical nephrology and dialysis techniques. He chairs the annual International CRRT Conference that is now in its 22nd year. He chaired the ISN Committee on AKI, is a founding member of the Acute Dialysis Quality Initiative (ADQI) and the Acute Kidney Injury network (AKIN). His research has informed the development of the RIFLE and AKIN diagnostic and staging criteria for AKI and development of KDIGO guidelines for AKI. He has been recognized as one of the Best Doctors in San Diego and the US for several years. In 2008 he was recognized by the American Nephrologists of Indian Origin and in March 2009 he was elected as a Fellow of the Royal College of Physicians in the UK. He received the ISN Bywaters Award for lifetime achievement in AKI in April 2011. He has most recently been appointed as the Director of the ISN 0by25 initiative to eliminate preventable deaths from AKI by 2025. He has trained over 50 post-doctoral fellows, of whom 17 have carried out their research projects with him. He received the M.B.B.S. degree (1976) from the Government Medical School in Amritsar, India, and the M.D. (1979) and D.M. (1981) degrees from the Post Graduate Institute of Medical Education and Research in Chandigarh, India. He subsequently completed a nephrology fellowship at the University of Rochester in Rochester New York and obtained his boards in Internal Medicine (1986) and Nephrology (1988). He has been on the faculty at San Diego since 1988.
Saber D. Barbar is specialist in Internal Medicine and Intensive Care Medicine, and holds a PhD in Life Science. He works as intensivist in the Anesthesiology and Critical Care Department at Nîmes University Hospital, France. His current research topics include the optimal timing of the renal replacement therapy, biomarkers of acute kidney injury, and septic AKI. He is the principal investigator of the IDEAL-ICU study, a randomized controlled trial examining timing of renal replacement therapy in septic AKI. He has authored or co-authored over 20 peer reviewed articles or book chapters. He has served as a reviewer for various peer-review journals and as expert in the field of critical care in different committees.
Professor of Medicine in the Division of Nephrology, Associate Director of ICU Nephrology, and Director of the CRRT Program at the University of Alabama at Birmingham